Sian Bigora

CIK: 0001799365

Transaction Breakdown

Open Market Buys (P)4 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (20.0%)

Derivative conversions

Awards (A)3 (30.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (10.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PCSA

Processa Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

PCSA
Processa Pharmaceuticals, Inc.
Apr 30, 2026
Purchase(P)
Direct
2K shares at avg. $2.71$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 30, 2026
Purchase(P)
Direct
2K shares at avg. $2.69$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 15, 2026
Purchase(P)
Direct
1.8K shares at avg. $2.97$5K
PCSA
Processa Pharmaceuticals, Inc.
Mar 31, 2026
Purchase(P)
Direct
2.1K shares at avg. $2.54$5K
PCSA
Processa Pharmaceuticals, Inc.
Jan 1, 2026
Exercise(M)
Direct
249 shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
96K shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Stock Options (Right to Buy)
Direct
288K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jul 24, 2025
Award(A)
Restricted Stock Units
Direct
1.7M shares-
PCSA
Processa Pharmaceuticals, Inc.
Apr 1, 2025
Tax Payment(F)
Direct
3.3K shares at avg. $0.41$1K
PCSA
Processa Pharmaceuticals, Inc.
Apr 1, 2025
Exercise(M)
Direct
15.1K shares-

		Type	Shares	Price		Ownership
Apr 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,971	$2.71	$5,341	Direct
Apr 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,986	$2.69	$5,342	Direct
Apr 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,799	$2.97	$5,343	Direct
Mar 31, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,107	$2.54	$5,341	Direct
Jan 1, 2026	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	249	-	$0	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	96,000	-	-	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Stock Options (Right to Buy)	288,000	-	-	Direct
Jul 24, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	1,659,185	-	-	Direct
Apr 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Tax Payment(F)	3,311	$0.41	$1,364	Direct
Apr 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	15,059	-	-	Direct

1-10 of 10 transactions

About Bigora Sian

Bigora Sian (SEC CIK 0001799365) files insider reports with the SEC as Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA).

Signal8 holds 9 ownership filings by Bigora Sian, all Form 4s, filed between Apr 11, 2025 and May 19, 2026. Those filings report 10 transactions, from Apr 1, 2025 to Apr 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bigora Sian's filings is in VERO BEACH, FL.

Recent filings by Bigora Sian

Apr 30, 2026: Open-market purchases of PCSA shares (2 lines, Form 4, code P).
Apr 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Mar 31, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Jan 1, 2026: Option exercise of PCSA shares (Form 4, code M).
Oct 1, 2025: Grants or awards of PCSA derivative securities (2 lines, Form 4, code A).

Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)

Ng George K, Chief Executive Officer
GUJRATHI SHEILA, Director
Yorke Justin W, Director
SKIBSTED RUSSELL, Chief Financial Officer
Pannu Geraldine, Director
Neal James R, Director

How to read Form 4 transaction codes